Key facts
- This page summarizes Robert Ross Carter's Form 4 filing for Oncology Institute, Inc. (TOI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Mar 2025, 17:27.
Robert Ross Carter - 26 Mar 2025 Form 4 Insider Report for Oncology Institute, Inc. (TOI)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- TOI
- Reported as of
- 26 Mar 2025
- Net transaction value
- +$10,000
- SEC form
- 4
- Accepted by SEC
- 28 Mar 2025, 17:27:58 UTC
- Prior SEC filing
- 20 Mar 2025
- Next SEC filing
- 02 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Hueppelsheuser, Attorney-in-fact for Robert Carter
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Ross Carter filed Form 4 for Oncology Institute, Inc. (TOI) on 28 Mar 2025.
Change
- Previous filing in this sequence was filed on 20 Mar 2025.
- Current net transaction value: +$10,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TOI
transaction
Common Stock
Purchase
- Transaction value
- $9,434
- Shares
- +9,056
- Change %
- +30%
- Price
- $1.04*
- Shares after
- 39,407
- Date
- 26 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TOI
transaction
Derivative
Common Warrant
Purchase
- Transaction value
- $566
- Shares
- +4,528
- Change %
- Price
- $0.1250
- Shares after
- 4,528
- Date
- 26 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,528
- Exercise price
- $1.20
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents securities purchased in a private placement transaction directly from the Company pursuant to a Securities Purchase Agreement, dated March 24, 2025 (the "Private Placement"). Pursuant to the terms of the Securities Purchase Agreement, the Company issued the reporting person Private Placement units consisting of two shares of the Company's common stock ("Common Stock") and a common warrant ("Common Warrant") to purchase one share of Common Stock (the "Private Placement Unit").
Footnote F2
The issuance of the securities to the reporting person pursuant to the Private Placement was approved by the Company's board of directors and was deemed an exempt transaction pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Footnote F3
Each Private Placement Unit was purchased at a price of $2.2084 per unit, with a cost per share of Common Stock of $1.0417 and a cost per Common Warrant of $0.1250.
Footnote F4
The reporting person may not exercise any portion of a Common Warrant to the extent that the reporting person would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately prior to or after giving effect to such exercise, as such percentage ownership is determined in accordance with Section 13(d) under the Exchange Act.